Marvel Biosciences announced a non-brokered private placement to raise up to $500,000 through unsecured convertible debentures with 12% annual interest, maturing in December 2027. The funds will support drug formulation, toxicology studies, and general working capital. The debentures can convert into common shares at $0.12 each, with conditions to prevent excessive ownership concentration. This financing move aims to advance Marvel's development of MB-204, a drug targeting neurological diseases like Parkinson's and Alzheimer's.
The FTSE 100 index fell slightly, dragged down by mining stocks reacting to China's slower GDP growth of 4.3% in Q2, its weakest in three years. Despite this, oil prices remained steady amid US-Iran tensions. PayPal shares jumped over 14% following r...
The Goldman Sachs Future Tech Leaders Equity ETF (GTEK) has delivered a 48.9% return year-to-date, nearly doubling the 25% return of the Vanguard Information Technology ETF (VGT). Unlike VGT, which heavily invests in mega-cap tech giants like Nvidia,...
